-
Signature
-
/s/ Kyle Nelson, attorney-in-fact
-
Issuer symbol
-
RXRX
-
Transactions as of
-
11 Aug 2025
-
Net transactions value
-
-$3,263,964
-
Form type
-
4
-
Filing time
-
13 Aug 2025, 21:03:16 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Gibson Christopher |
Chief Executive Officer, Director |
C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY |
/s/ Kyle Nelson, attorney-in-fact |
11 Aug 2025 |
0001856369 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
RXRX |
Class A Common Stock |
Conversion of derivative security |
$0 |
+423,666 |
+39% |
$0.000000 |
1,504,919 |
11 Aug 2025 |
Direct |
F1, F2 |
| transaction |
RXRX |
Class A Common Stock |
Sale |
$2,641,584 |
-500,300 |
-33% |
$5.28 |
1,004,619 |
11 Aug 2025 |
Direct |
F2 |
| transaction |
RXRX |
Class A Common Stock |
Gift |
$0 |
-10,000 |
-1% |
$0.000000 |
994,619 |
11 Aug 2025 |
Direct |
F2, F3 |
| transaction |
RXRX |
Class A Common Stock |
Conversion of derivative security |
$0 |
+100,000 |
|
$0.000000 |
100,000 |
11 Aug 2025 |
by LAHWRAN-3 LLC |
F1, F2, F4 |
| transaction |
RXRX |
Class A Common Stock |
Sale |
$528,000 |
-100,000 |
-100% |
$5.28 |
0 |
11 Aug 2025 |
by LAHWRAN-3 LLC |
F2, F4 |
| transaction |
RXRX |
Class A Common Stock |
Conversion of derivative security |
$0 |
+17,875 |
|
$0.000000 |
17,875 |
11 Aug 2025 |
by Gibson Family Trust |
F1, F2, F5 |
| transaction |
RXRX |
Class A Common Stock |
Sale |
$94,380 |
-17,875 |
-100% |
$5.28 |
0 |
11 Aug 2025 |
by Gibson Family Trust |
F2, F5 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
RXRX |
Class B Common Stock |
Conversion of derivative security |
$0 |
-423,666 |
-7.2% |
$0.000000 |
5,473,034 |
11 Aug 2025 |
Class A Common Stock |
423,666 |
$0.000000 |
Direct |
F1, F2, F6 |
| transaction |
RXRX |
Class B Common Stock |
Conversion of derivative security |
$0 |
-100,000 |
-21% |
$0.000000 |
386,000 |
11 Aug 2025 |
Class A Common Stock |
100,000 |
$0.000000 |
by LAHWRAN-3 LLC |
F1, F2, F4, F6 |
| transaction |
RXRX |
Class B Common Stock |
Conversion of derivative security |
$0 |
-17,875 |
-26% |
$0.000000 |
50,000 |
11 Aug 2025 |
Class A Common Stock |
17,875 |
$0.000000 |
by Gibson Family Trust |
F1, F2, F5, F6 |
| holding |
RXRX |
Class B Common Stock |
|
|
|
|
|
388,000 |
11 Aug 2025 |
Class A Common Stock |
0 |
$0.000000 |
by LAHWRAN-4 LLC |
F6, F7 |
| holding |
RXRX |
Stock Option (Right to Buy) |
|
|
|
|
|
1,050,567 |
11 Aug 2025 |
Class A Common Stock |
0 |
$7.25 |
Direct |
F8 |
| holding |
RXRX |
Stock Option (Right to Buy) |
|
|
|
|
|
666,898 |
11 Aug 2025 |
Class A Common Stock |
0 |
$10.09 |
Direct |
F9 |
| holding |
RXRX |
Stock Option (Right to Buy) |
|
|
|
|
|
813,600 |
11 Aug 2025 |
Class A Common Stock |
0 |
$8.55 |
Direct |
F10 |
| holding |
RXRX |
Stock Option (Right to Buy) |
|
|
|
|
|
399,002 |
11 Aug 2025 |
Class A Common Stock |
0 |
$11.40 |
Direct |
F11 |
| holding |
RXRX |
Stock Option (Right to Buy) |
|
|
|
|
|
5,436 |
11 Aug 2025 |
Class A Common Stock |
0 |
$11.40 |
Direct |
|
| holding |
RXRX |
Stock Option (Right to Buy) |
|
|
|
|
|
282,500 |
11 Aug 2025 |
Class A Common Stock |
0 |
$2.48 |
Direct |
F12 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: